尤瑞克林联合降纤酶治疗急性进展型脑梗死的疗效观察

Curative effect of urinary kallidinogenase joint defibrase on acute progressing cerebral infarction

目的探讨尤瑞克林联合降纤酶治疗急性进展型脑梗死患者的临床疗效。方法将近年来我院收治的90例急性进展型脑梗死患者随机分为研究组与对照组各45例,对照组采用尤瑞克林治疗,研究组采用尤瑞克林联合降纤酶治疗,观察比较两组患者治疗前后神经功能损伤情况及不良反应。结果治疗后两组患者的神经损伤情况均得到改善,且NIHSS得分与治疗前比较,差异有统计学意义(P<0.05)。研究组的NIHSS得分明显低于对照组(P<0.05)。研究组治疗后的总有效率为86.67%,明显高于对照组的62.22%(χ2=4.23,P<0.05)。研究组的不良反应发生率为2.22%,明显低于对照组的6.67%(χ2=3.73,P<0.05)。结论尤瑞克林联合降纤酶治疗急性进展型脑梗死疗效确切,不良反应少,安全可靠,值得临床推广。

Objective To observe curative effect of urinary kallidinogenase joint defibrase on acute progressing cerebral infarction. Methods Collected 90 cases of acute progressing cerebral infarction were randomly divided into two groups. The control group （n = 45） was treated with urinary kallidinogenase. The study group （n = 45） was treated with urinary kallidino- genase joint defibrase.Observed and compared Neurological damage and adverse reaction of the two groups. Results After treatment, nerve damage of the two groups were improved and NIHSS scores were significantly higher than before （P 〈 0.05）. NIHSS score of the study group was significantly lower than before （P 〈 0.05）. The total effective rate of the study group was 86.67%, was significantly higher than the control group （62.22%） （X^2=4.23 ,P 〈 0.05）. Adverse reaction rate of the study group was 2.22%, was significantly lower than the control group （6.67%） （X^2=3.73 ,P 〈 0.05）. Conclusion Urinary kallidino- genase joint defibrase is safe,reliable and has definite effect on acute progressing cerebral infarction.